Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.

Authors

Affiliations

¹ Institute of Clinical Research, Moscow, Russian Federation [email protected].
² City Clinical Hospital No 52, Moscow, Russian Federation.
³ City Clinical Hospital No 4, Moscow, Russian Federation.
⁴ Moscow State University of Medicine and Dentistry n.a. AI Yevdokimov, Moscow, Russian Federation.
⁵ City Clinical Hospital No 24, Moscow, Russian Federation.
⁶ Imperial College London, London, UK.

No abstract available

Keywords: COVID-19; cytokines; therapeutics.

Publication types

Letter
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Azetidines / therapeutic use*
COVID-19 Drug Treatment*
Female
Humans
Janus Kinase Inhibitors / therapeutic use*
Male
Middle Aged
Piperidines / therapeutic use*
Prospective Studies
Purines / therapeutic use*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Russia
SARS-CoV-2
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Azetidines
Janus Kinase Inhibitors
Piperidines
Purines
Pyrazoles
Pyrimidines
Sulfonamides
tofacitinib
baricitinib